%%%%%%%%% A
\newacronym{ADA}{ADA}{anti-drug antibodies}
\newacronym{AE}{AE}{adverse event}
\newacronym{AIC}{AIC}{Akaike information criterion}
\newacronym{ALAG}{ALAG}{oral absorption lag time}
\newacronym{ASCII}{ASCII}{American Standard Code for Information Interchange}
\newacronym{AST}{AST}{aspartate transaminase}
\newacronym[sort=AUC]{AUC}{\ensuremath{\mathit{AUC}}}{area under the concentration-time curve}
\newacronym[sort=AUCss]{AUCss}{\ensuremath{\mathit{AUC_{\mathrm{ss}}}}}{area under the concentration-time curve for a dosing interval at steady state}
\newacronym[sort=AUCC]{AUCC}{\ensuremath{AUC_{\mathrm{cumulative}}}}{cumulative area under the concentration-time curve since first dose}
\newacronym[sort=AUC50]{AUCC50}{\ensuremath{AUC50}}{area under the concentration-time curve at 50\% of the maximum effect}

%%%%%%%%% B
\newacronym{BIC}{BIC}{Bayesian information criterion}
\newacronym{BID}{BID}{twice daily}
\newacronym{BL}{BL}{baseline}
\newacronym{BLQ}{BLQ}{below limit of quantification}
\newacronym{BMI}{BMI}{body mass index}
\newacronym{BSA}{BSA}{body surface area}
\newacronym{BTR}{BTR}{best tumor response}

%%%%%%%%% C
\newacronym{CATD}{CATD}{computer assisted clinical trial design}
\newacronym[sort=Cavg]{Cavg}{\ensuremath{C_{\mathrm{avg}}}}{average concentration during the dosing interval}
\newacronym[sort=Cavgc]{Cavgc}{\ensuremath{C_{\mathrm{avg,\sim cumulative}}}}{average concentration since first dose calculated as $AUC_{\mathrm{cumulative}}$/TAFD}
\newacronym[sort=Cavgss]{Cavgss}{\ensuremath{C_{\mathit{avg,ss}}}}{average concentration during the dosing interval at steady state}
\newacronym[plural=CIs, firstplural=confidence intervals (CIs)]{CI}{CI}{confidence interval}
\newacronym{CKD}{CKD}{chronic kidney disease}
\newacronym[sort=CLi]{CLi}{\ensuremath{\mathit{CL_i}}}{individual-specific systemic clearance}
\newacronym[sort=CLF]{CLF}{\ensuremath{\mathit{CL/F}}}{apparent clearance after oral dosing}
\newacronym[sort=Cmax]{Cmax}{\ensuremath{C_{\mathrm{max}}}}{maximum concentration in the dosing interval}
\newacronym[sort=Cmaxss]{Cmaxss}{\ensuremath{C_{\mathrm{max,ss}}}}{maximum concentration in the dosing interval at steady state}
\newacronym[sort=Cmin]{Cmin}{\ensuremath{C_{\mathrm{min}}}}{minimum concentration in the dosing interval}
\newacronym[sort=Cminss]{Cminss}{\ensuremath{C_{\mathrm{min,ss}}}}{minimum concentration in the dosing interval at steady state}
\newacronym{CRCL}{CRCL}{Cockcroft-Gault calculated creatinine clearance based on total body weight}
\newacronym{CSV}{CSV}{comma separated values}
\newacronym{CTCAE}{CTCAE}{Common Terminology Criteria for Adverse Events}
\newacronym{CUI}{CUI}{clinical utility index}
\newacronym{CVP}{CV\%}{percent coefficient of variation}
\newacronym{CWRES}{CWRES}{conditional weighted residual}
\newacronym{CWRESI}{CWRESI}{conditional weighted residual with interaction}

%%%%%%%%% D
\newacronym{D1}{D1}{zero order absorption duration}
\newacronym{df}{df}{degrees of freedom}

%%%%%%%%% E
\newacronym[plural=EBEs, firstplural=empirical Bayes estimates (EBEs)]{EBE}{EBE}{empirical Bayes estimates}
\newacronym{ECOG}{ECOG}{Eastern Cooperative Oncology Group}
\newacronym{eGFR}{eGFR}{estimated glomerular filtration rate}
\newacronym{EMA}{EMA}{European Medicines Agency}
\newacronym{Emax}{Emax}{maximum effect}
\newacronym{EM}{EM}{expectation maximization}
\newacronym{ER}{ER}{exposure-response}
\newacronym{ES}{ES}{exposure-safety}
\newacronym{ETA}{ETA}{interindividual random effect}
\newacronym{ETHN}{ETHN}{ethnicity}
\newacronym{EVID}{EVID}{event ID}
\newacronym{EWRES}{EWRES}{expected weighted residual}

%%%%%%%%% F
\newacronym[sort=f]{F}{F}{absolute bioavailability}
\newacronym{FDA}{FDA}{United States Food and Drug Administration}
\newacronym{FO}{FO}{first-order}
\newacronym{FOCE}{FOCE}{first-order conditional estimation}
\newacronym{FOCEI}{FOCEI}{first-order conditional estimation with $\eta$--$\epsilon$\ interaction}
\newacronym{FPG}{FPG}{fasting plasma glucose}

%%%%%%%%% G
\newacronym{gam}{GAM}{generalized additive model}
\newacronym{gh}{HbA1c}{glycosylated hemoglobin}
\newacronym{glm}{GLM}{generalized linear model}
\newacronym{GOF}{GOF}{goodness of fit}

%%%%%%%%% H
\newacronym{hr}{hr}{hours}

%%%%%%%%% I
\newacronym{IBW}{IBW}{ideal body weight}
\newacronym{IGF-1}{IGF-1}{insulin-like growth factor 1}
\newacronym{IIV}{IIV}{interindividual variability}
\newacronym{IM}{IM}{intramuscular}
\newacronym{Imax}{Imax}{maximum inhibition}
\newacronym{IMP}{IMP}{Monte Carlo importance sampling}
\newacronym{IOV}{IOV}{interoccasion variability}
\newacronym{ITS}{ITS}{iterative two stage}
\newacronym{IV}{IV}{intravenous}

%%%%%%%%% J

%%%%%%%%% K
\newacronym[sort=ka]{ka}{\ensuremath{k_a}}{absorption rate constant}
\newacronym{kg}{kg}{kilograms}

%%%%%%%%% L
\newacronym{L}{L}{liters}
\newacronym{LASSO}{LASSO}{least absolute shrinkage and selection operator}
\newacronym{LL}{LL}{log likelihood}
\newacronym{LLQ}{LLQ}{lower limit of quantification}
\newacronym{LRT}{LRT}{likelihood ratio test}

%%%%%%%%% M
\newacronym{MAP}{MAP}{maximum \textit{a posteriori}}
\newacronym{mcg}{mcg}{micrograms}
\newacronym{MCMC}{MCMC}{Markov chain Monte Carlo}
\newacronym{MDRD}{MDRD}{modification of diet in renal disease}
\newacronym{mg}{mg}{milligrams}
\newacronym{mL}{mL}{milliliters}
\newacronym{MS}{M\&S}{modeling and simulation}
\newacronym{MSP}{MSP}{modeling and simulation plan}

%%%%%%%%% N
\newacronym{NCA}{NCA}{noncompartmental analysis}
\newacronym{NCI}{NCI}{National Cancer Institute}
\newacronym{NCI-ODWG}{NCI-ODWG}{National Cancer Institute organ dysfunction working group}
\newacronym{Neff}{Neff}{effective sample size}
\newacronym{ng}{ng}{nanograms}
\newacronym[sort=N]{etai}{\ensuremath{\eta i}}{individual random effects}
\newacronym{NPDE}{NPDE}{normalized prediction distribution error}


%%%%%%%%% O
\newacronym{ODWG}{ODWG}{organ dysfunction working group}
\newacronym{OFV}{OFV}{objective function value}

%%%%%%%%% P
\newacronym{PD}{PD}{pharmacodynamic}
\newacronym{PK}{PK}{pharmacokinetic}
\newacronym{pg}{pg}{picograms}
\newacronym{PO}{PO}{orally}
\newacronym[plural=PPCs, firstplural=posterior predictive checks (PPCs)]{PPC}{PPC}{posterior predictive check}


%%%%%%%%% Q
\newacronym{QD}{QD}{once daily}
\newacronym[sort=QF]{QF}{\ensuremath{\mathit{Q/F}}}{apparent (oral) intercompartmental clearance}
\newacronym{QQ}{QQ}{quantile-quantile}

%%%%%%%%% R
\newacronym{RES}{RES}{residuals}
\newacronym{Rhat}{R-hat}{Gelman-Rubin diagnostics}
\newacronym{ROPE}{ROPE}{region of practical equivalence}

%%%%%%%%% S
\newacronym{SAEM}{SAEM}{stochastic approximation expectation maximization}
\newacronym{SAS}{SAS XPORT}{Statistical Analysis System Transport File Format}
\newacronym{SC}{SC}{subcutaneous}
\newacronym{SCR}{SCR}{serum creatinine}
\newacronym{SD}{SD}{standard deviation}
\newacronym{SE}{SE}{standard error}
\newacronym{SDTM}{SDTM}{study data tabulation model}
\newacronym{ss}{ss}{steady state}
\newacronym{SXPORT}{SAS XPORT}{Statistical Analysis System Transport File Format}


%%%%%%%%% T
\newacronym{TAD}{TAD}{time after (most recent) dose}
\newacronym{TAFD}{TAFD}{time after first dose}
\newacronym[sort=TVP]{TVP}{\ensuremath{\mathit{TVP}}}{typical value of a model parameter  $P$}
\newacronym{T2DM}{T2DM}{type 2 diabetes mellitus}
\newacronym[sort=t]{hl}{\ensuremath{t_{1/2}}}{elimination half-life}
\newacronym{TMDD}{TMDD}{target-mediated drug disposition}


%%%%%%%%% U
\newacronym{UKPDS}{UKPDS}{United Kingdom prospective diabetes study}

%%%%%%%%% V
\newacronym[sort=VF]{VF}{\ensuremath{V/F}}{apparent volume of distribution after oral dosing}
\newacronym[sort=V2F]{V2F}{\ensuremath{V_2/F}}{apparent central volume of distribution after oral dosing}
\newacronym[sort=V3F]{V3F}{\ensuremath{\mathit{V_3/F}}}{apparent peripheral volume of distribution after oral dosing}
\newacronym{VPC}{VPC}{visual predictive check}

%%%%%%%%% W
\newacronym{WRES}{WRES}{weighted residuals}
\newacronym{WT}{WT}{subject weight}

%%%%%%%%% X
\newacronym[sort=X]{chi2}{\ensuremath{\chi^2}}{chi-squared distribution}


%%%%%%%%% Y

%%%%%%%%% Z
